Cargando…

Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson’s Disease: Experience in Clinical Trials

BACKGROUND: Due to the short half-life of levodopa, immediate-release carbidopa-levodopa (IR CD-LD) produces fluctuating LD concentrations, contributing to a risk of eventual motor complications. IPX066 was designed to rapidly attain therapeutic LD concentrations and maintain them to allow a dosing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nausieda, Paul A., Hsu, Ann, Elmer, Lawrence, Gil, Ramon A., Spiegel, Joerg, Singer, Carlos, Khanna, Sarita, Rubens, Robert, Kell, Sherron, Modi, Nishit B., Gupta, Suneel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927929/ https://www.ncbi.nlm.nih.gov/pubmed/26444090 http://dx.doi.org/10.3233/JPD-150622

Ejemplares similares

Long-Term Treatment with Extended-Release Carbidopa–Levodopa (IPX066) in Early and Advanced Parkinson’s Disease: A 9-Month Open-Label Extension Trial
por: Waters, Cheryl H., et al.
Publicado: (2015)

Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis
por: LeWitt, Peter A., et al.
Publicado: (2018)

Population Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of Carbidopa–Levodopa, and Immediate-Release Carbidopa–Levodopa in Patients With Advanced Parkinson’s Disease
por: Mao, Zhongping, et al.
Publicado: (2013)

Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations
por: Morgan, John C., et al.
Publicado: (2018)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

Dose‐Response Analysis of the Effect of Carbidopa‐Levodopa Extended‐Release Capsules (IPX066) in Levodopa‐Naive Patients With Parkinson Disease
por: Mao, Zhongping Lily, et al.
Publicado: (2016)

Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules
por: Modi, Nishit B., et al.
Publicado: (2019)

Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers
por: Yao, Hsuan-Ming, et al.
Publicado: (2016)

Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
por: LeWitt, Peter, et al.
Publicado: (2023)

Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations
por: Modi, Nishit B., et al.
Publicado: (2019)

Pharmacokinetics of Rytary(®), An Extended-Release Capsule Formulation of Carbidopa–Levodopa
por: Mittur, Aravind, et al.
Publicado: (2017)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
por: Hauser, Robert A, et al.
Publicado: (2018)

IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial
por: Hauser, Robert A., et al.
Publicado: (2023)

P066 Abstract Withdrawn
Publicado: (2021)

Magnetostructural transformation and magnetocaloric effect of Sn-bonded Mn(0.66)Fe(0.34)Ni(0.66)Fe(0.34)Si(0.66)Ge(0.34) composite
por: Si, Yu, et al.
Publicado: (2018)

Levodopa‐carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation
por: Rosebraugh, Matthew, et al.
Publicado: (2019)

Design of a ß=0.66 monocell cavity
por: Losito, R
Publicado: (1998)

O066. Kynurenine pathway metabolites in cluster headache
por: Curto, Martina, et al.
Publicado: (2015)

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy
por: Espay, Alberto J., et al.
Publicado: (2017)

LOW DOSE LEVODOPA IN TARDIVE DYSKINESIA
por: Sethi, Sujata, et al.
Publicado: (1990)

Formulation Optimization of a Palm-Based Nanoemulsion System Containing Levodopa
por: Zainol, Syafinaz, et al.
Publicado: (2012)

Model-based optimization of controlled release formulation of levodopa for Parkinson’s disease
por: Arav, Yehuda, et al.
Publicado: (2023)

O066 The Lived Experience of Narcolepsy - From Symptoms to Stigma
por: Schokman, A, et al.
Publicado: (2023)

Pharmaceutical and pharmacokinetic evaluation of a newly formulated multiparticulate matrix of levodopa and carbidopa
por: Imbeah, Emelia Priscilla, et al.
Publicado: (2022)

P066. Migraine with aura in the locker room: 4 case reports
por: Bernetti, Laura, et al.
Publicado: (2015)

MON-LB066 Older Self Neglect as an Unusual Presentation in Panhypopituitarism
por: Sultana, Tallat, et al.
Publicado: (2019)

PSAT066 Adrenal Insufficiency Associated with Amyloidosis and Sickle Cell Disease
por: Thi, Wai Phyo, et al.
Publicado: (2022)

P1048: PHARMACOKINETIC AND PHARMACODYNAMIC EFFECTS OF RUSFERTIDE IN POLYCYTHEMIA VERA: RESULTS FROM AN ONGOING PHASE 2 STUDY IN PATIENTS WITH ELEVATED HEMATOCRIT VALUES
por: Kremyanskaya, Marina, et al.
Publicado: (2023)

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease
por: Margolesky, Jason, et al.
Publicado: (2017)

P066: Risk factors of vancomycin-resistant enterococcus colonization in hemologic patients
por: Mioljevic, V, et al.
Publicado: (2013)

AB066. The diagnostic value of narrow-band imaging for flat bladder lesions
por: Chang, Yifan, et al.
Publicado: (2018)

ODP066 Impact of Comorbid Adrenal Insufficiency on Outcomes of Infective Endocarditis Hospitalizations
por: Akaho, Elikplim, et al.
Publicado: (2022)

Factors associated with complications after percutaneous nephrolithotomy: an analysis of 1,066 cases
por: Said, Danniel Frade, et al.
Publicado: (2023)

BF066, a Novel Dual Target Antiplatelet Agent without Significant Bleeding
por: Pan, ChangE, et al.
Publicado: (2012)

SUN-066 Circulating Irisin and Correlation with Antioxidant Systems in Different Models of Heart Failure
por: Vergani, Edoardo, et al.
Publicado: (2019)

Corneal Ulcer Treated with 0.66% Nanoemulsion Povidone-Iodine: A Case Report
por: Bordin, Paolo
Publicado: (2020)

O066 The Impact of Work Break Characteristics on Sleep Duration in Heavy Vehicle Drivers
por: Harris, R, et al.
Publicado: (2022)

P066 The Relationship between Chronic Breathlessness and Perceived Sleep Quality in Adult Australian
por: Toson, B, et al.
Publicado: (2023)

Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
por: Conti, Valeria, et al.
Publicado: (2022)

P01.36. Assessment of commercial formulations of mucuna pruriens seeds for Levodopa (L-DOPA) content
por: Soumyanath, A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_sbup51sfhbg3k9teo7qiqi9f0h